Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | TEC | P42680 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23450731 | 1.00 | BTK (0.46) | BTKHCAR1HTR6HPGDSBACE1 | |
| SCHEMBL18289974 | 1.00 | BTK (0.46) | BTKHCAR1HTR6HPGDSBACE1 | |
| SCHEMBL18644666 | 0.94 | SRC (0.45) | BTKHCAR1HPGDSBACE1CTSD | |
| SCHEMBL18285551 | 0.85 | BTK (0.45) | BTKEGFRTECCD69JAK2 | |
| SCHEMBL18285554 | 0.85 | BTK (0.45) | BTKEGFRTECCD69JAK2 | |
| SCHEMBL29737131 | 0.85 | KDM4E (0.37) | BTKHCAR1EGFRSRCPIK3CA | |
| SCHEMBL24590579 | 0.85 | KDM4E (0.37) | BTKHCAR1EGFRSRCPIK3CA | |
| SCHEMBL16321781 | 0.85 | SRC (0.49) | BTKHCAR1HPGDSBACE1CTSD | |
| SCHEMBL16321782 | 0.85 | SRC (0.49) | BTKHCAR1HPGDSBACE1CTSD | |
| SCHEMBL18818279 | 0.83 | HCAR1 (0.41) | BTKHCAR1HTR6HPGDSFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4112618-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | BTK 1/4885HCAR1 4128/4885HTR6 4214/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | BTK 1/4885HCAR1 4128/4885HTR6 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.